# Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

> **NCT06120972** · PHASE2 · WITHDRAWN · sponsor: **Alexander B Olawaiye, MD**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib tablet

## Key facts

- **NCT ID:** NCT06120972
- **Lead sponsor:** Alexander B Olawaiye, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor terminated due to Olaparib losing patent
- **Last updated:** 2025-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06120972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06120972, "Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06120972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*